AstraZeneca
Stock Forecast, Prediction & Price Target
AstraZeneca (AZN) stock Price Target by analysts
$88.5
Potential upside: 11.26%
AstraZeneca price prediction
What is AstraZeneca stock analysts` prediction?
AstraZeneca stock forecast: Based on 1 Wall Street analysts` predicted price targets for AstraZeneca in the last 3 months, the avarage price target is $88.5, with a high forecast of $NaN. The average price target represents a 11.26% change from the last price of $79.54.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
AstraZeneca stock Price Target by analysts
Full breakdown of analysts given AstraZeneca price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/3 | 10 months ago | $88 10.63% upside | $81.19 | StreetInsider | Previous targets (2) |
Etzer Darout BMO Capital | 0% 0/3 | 12 months ago | $89 11.89% upside | $79.94 | StreetInsider | Previous targets (2) |
John Eade Argus Research | 0% 0/1 | over 1 year ago | $85 6.86% upside | $76.84 | StreetInsider | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/3 | over 1 year ago | $82 3.09% upside | $76.74 | StreetInsider | Previous targets (2) |
Andrew Berens Leerink Partners | 0% 0/1 | about 2 years ago | $79 -0.67% downside | $64.86 | Benzinga | Previous targets (0) |
Unknown BMO Capital | N/A | over 2 years ago | $82 3.09% upside | $69.5 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $78 -1.93% downside | $65.09 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $75 -5.70% downside | $67.17 | Benzinga | N/A |
AstraZeneca Financial Estimates
AstraZeneca Revenue Estimates
AstraZeneca EBITDA Estimates
AstraZeneca Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $37.41B N/A | $44.35B 18.53% | $45.81B 3.29% | Avg: $55.40B Low: $54.51B High: $55.96B avg. 20.94% | Avg: $58.57B Low: $57.33B High: $59.25B avg. 5.72% | Avg: $62.41B Low: $61.09B High: $63.14B avg. 6.55% | Avg: $65.03B Low: $63.65B High: $65.78B avg. 4.18% |
Net Income
% change YoY
| $112M N/A | $3.28B 2835.71% | $5.95B 81.11% | Avg: $10.48B Low: $19.22B High: $23.69B avg. 76.13% | Avg: $11.74B Low: $22.11B High: $25.74B avg. 12.00% | Avg: $17.69B Low: $17.20B High: $17.96B avg. 50.63% | Avg: $19.11B Low: $18.59B High: $19.40B avg. 8.02% |
EBITDA
% change YoY
| $7.56B N/A | $9.32B 23.29% | $13.42B 43.90% | Avg: $14.60B Low: $14.37B High: $14.75B avg. 8.84% | Avg: $15.44B Low: $15.11B High: $15.62B avg. 5.72% | Avg: $16.45B Low: $16.11B High: $16.64B avg. 6.55% | Avg: $17.14B Low: $16.78B High: $17.34B avg. 4.18% |
EPS
% change YoY
| $0.04 N/A | $1.06 2550% | $1.92 81.13% | Avg: $6.78 Low: $6.15 High: $7.58 avg. 253.34% | Avg: $7.65 Low: $7.08 High: $8.24 avg. 12.78% | Avg: $5.66 Low: $5.51 High: $5.75 avg. -25.96% | Avg: $6.12 Low: $5.95 High: $6.21 avg. 8.02% |
Operating Expenses
% change YoY
| $23.92B N/A | $28.20B 17.88% | $29.57B 4.87% | Avg: $24.04B Low: $23.65B High: $24.28B avg. -18.72% | Avg: $25.41B Low: $24.87B High: $25.70B avg. 5.72% | Avg: $27.08B Low: $26.50B High: $27.39B avg. 6.55% | Avg: $28.21B Low: $27.61B High: $28.54B avg. 4.18% |
FAQ
What is AstraZeneca stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 36.69% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is 19.22B, average is 10.48B and high is 23.69B.
What is AstraZeneca stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 9.35% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $54.51B, average is $55.40B and high is $55.96B.
What is AstraZeneca stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 62.04% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is $6.15, average is $6.78 and high is $7.58.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering AstraZeneca stock. The most successful analyst is Etzer Darout.